FDA 483 - UBE Corporation - September 28, 2017
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Ube Industries, Ltd. dba Ube API and Intermediates Factory in Ube, Japan, revealed significant deficiencies in their quality unit's oversight of cGMPs for active pharmaceutical ingredients. The firm failed to maintain electronic raw data, lacked adequate audit trails for laboratory instruments and manufacturing control systems, and had uncontrolled issuance of critical cGMP worksheets. These issues indicate a systemic breakdown in data integrity and quality management.
ID · 440cfa7a-07e2-4c2a-8ccb-fd97ea7068f8